Comprehensive Psychiatry
Volume 43, Issue 6 , Pages 469-473 , November 2002

Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia

References 

  1. Falloon IRH, Liberman RP. Interactions between drug and psychosocial therapy in schizophrenia. Schizophr Bull. 1983;9:543–554
  2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996;153:321–330
  3. Marder SR, Wirshing SC, Mintz J, Mckenzie J, Johnston K, Eckman TA, et al.  Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996;153:1585–1592
  4. Corrigan PW, Wallace CJ, Schade ML, Green MF. Learning medication self-management skills in schizophrenia: relationships with cognitive deficits and psychiatric symptoms. Behav Ther. 1994;25:5–15
  5. Flynn SW, Macewan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, et al.  An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 1998;31:25–29
  6. Smith TE, Hull JW, Romanelli S, Fertuck E, Weiss KA. Symptoms and neurocognition as rate limiters in skills training for psychotic patients. Am J Psychiatry. 1999;156:1817–1818
  7. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry. 1996;41(2 Suppl):S35–40
  8. Meltzer HY, Mcgurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233–255
  9. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, Mcgurk S, et al.  Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am J Psychiatry. 1997;154:799–804
  10. Earnst KS. Taylor SF, Smet IC, Goldman RS, Tandon R, Berent S. The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia. Schizophr Res. 1999;40:255–256
  11. Berman I, Klegon D, Fiedosewicz H, Chang H. The effect of novel antipsychotics on cognitive functioning. Psychiatr Ann. 1999;29:643–646
  12. Addington J, Addington D. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol. Can J Psychiatry. 1997;42:983–991
  13. Kane J, Honigfeld G, Singer J, Meltzer H, Group CCS. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–796
  14. Glynn SM, Liberman RP, Bowen L, Kuehnel TG, Marshall BD, Gnanamuthu S. The Clinical Research Unit at Camarillo State Hospital. In:  Corrigan PW,  Liberman RP editor. Behavior Therapy in Psychiatric Hospitals. New York, NY: Springer; 1994;p. 39–60
  15. Harvey PD, Keefe RFE. Studies of the cognitive changes in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184
  16. Paul GL, Tobias LT, Holly BL. Maintenance psychotropic drugs in the presence of active treatment programs: a triple blind withdrawal study with long-term mental patients. Arch Gen Psychiatry. 1972;27:106–115
  17. Kern RS, Green MF, Wallace CJ. Declarative and procedural learning in schizophrenia: a test of the integrity of divergent memory systems. Cognit Neuropsychiatry. 1997;2:39–50
  18. Meyers PS, Bond GR, Tunis SL, Mccoy ML. Comparisons between atypical and traditional antipsychotics in work outcome for clients in a psychiatric rehabilitation program. Psychiatr Serv. 2004; In Press
  19. Aquila R. Vocational outcomes associated with conventional vs. atypical antipsychotic medications. Presented at the Annual Meeting of the American Psychiatric Association; May 16-20, 1999; Chicago, IL.
  20. Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, Mcgurk S, et al.  Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry. 1998;44:726–732
  21. Kee KS, Kern RS, Green MF. Perception of emotion and neurocognitive functioning in schizophrenia: what's the link?. Psychiatry Res. 1998;81:57–65
  22. Spaulding WD, Fleming SK, Reed D, Sullivan M, Storzbach D, Lam M. Cognitive functioning in schizophrenia: Implications for psychiatric rehabilitation. Schizophr Bull. 1999;25:275–290
  23. Liberman RP, Marder SR, Marshall BD, Mintz J, Kuehnel TG. Biobehavioral therapy: Interactions between pharmacotherapy and behavior therapy in schizophrenia. In:  Wykes T,  Tarrier N,  Lewis S editor. Outcome and Innovation in Psychological Treatment of Schizophrenia. London, UK: Wiley; 1998;p. 179–199

PII: S0010-440X(02)00046-9

doi: 10.1053/comp.2002.33499

Comprehensive Psychiatry
Volume 43, Issue 6 , Pages 469-473 , November 2002

Article Tools